Emapalumab as a Life-Saving Therapy for Macrophage Activation Syndrome in Refractory Systemic Juvenile Idiopathic Arthritis with Trisomy 21
Cite this article as: Akay N, Aslan E, Gul U, Konte EK, Yildiz M, Sahin S. Emapalumab as a life-saving therapy for macrophage activation syndrome in refractory systemic juvenile idiopathic arthritis with trisomy 21. Turk Arch Pediatr. 2025;60(6):695-699.
Authors
- Nergis Akay (ORCID: https://orcid.org/0000-0001-6102-4055)
- Mehmet Yıldız (ORCID: https://orcid.org/0000-0002-7834-4909)
- Ece Aslan (ORCID: https://orcid.org/0000-0001-8976-1356)
- Sezgin Şahin (ORCID: https://orcid.org/0000-0002-5365-3457)
- Ümit Gül (ORCID: https://orcid.org/0000-0002-1282-8273)
Institutions
- Istanbul University-Cerrahpaşa (TR)
Publication Details
- Journal
- Turkish Archives of Pediatrics
- Published
- 2025-11-03
- DOI
- https://doi.org/10.5152/turkarchpediatr.2025.25394
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00